AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate
Yahoo Finance · 1 day ago
Search results
May 7, 2024 · AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives.
- 168.59Add to watchlist+2.03 (+1.22%)At close: Fri. Jun 14, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Market closed
- Open166.47High169.24Low166.00
- Mkt Cap297.71BP/E (TTM)50.33Div & Yield6.20 & 3.68%
- Prev. Close166.5652 Wk. Low130.9652 Wk. High182.89
What analysts are sayingTop storiesRelated stocks
Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing.
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74.
May 7, 2024 · AbbVie discovers and delivers innovative medicines and solutions that enhance people’s lives.
AbbVie is a global biopharmaceutical company with focus and capabilities to address some of the world's greatest health challenges. AbbVie discovers, develops, and commercializes advanced therapies that have an impact on people's lives.
Feb 12, 2024 · AbbVie Completes Acquisition of ImmunoGen. Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio. ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative ...
AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer. June 06, 2024.
May 7, 2024 · Our Patient Assistance Programs are intended for people that live in the United States, have limited or no health insurance coverage and demonstrate qualifying financial need. In 2022, we assisted nearly 200,000 people. Applying to myAbbVie Assist is simple.
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues...
Mar 25, 2024 · With AbbVie's therapeutic area leadership and expertise in global development, they are the right company to further advance NX-13." NLRX1 regulates immunometabolism and inflammation, and its activation impacts multiple mechanisms of inflammatory bowel disease (IBD) pathogenesis.
